CN107397975A - 抗感染医用创面敷料及其制备方法 - Google Patents
抗感染医用创面敷料及其制备方法 Download PDFInfo
- Publication number
- CN107397975A CN107397975A CN201710515624.0A CN201710515624A CN107397975A CN 107397975 A CN107397975 A CN 107397975A CN 201710515624 A CN201710515624 A CN 201710515624A CN 107397975 A CN107397975 A CN 107397975A
- Authority
- CN
- China
- Prior art keywords
- parts
- bacteria cellulose
- water extract
- added
- medical use
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 34
- 230000002924 anti-infective effect Effects 0.000 title claims abstract description 26
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 66
- 241000894006 Bacteria Species 0.000 claims abstract description 49
- 239000001913 cellulose Substances 0.000 claims abstract description 44
- 229920002678 cellulose Polymers 0.000 claims abstract description 44
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 30
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 claims abstract description 30
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims abstract description 29
- 241000196324 Embryophyta Species 0.000 claims abstract description 26
- 239000012153 distilled water Substances 0.000 claims abstract description 26
- -1 PAHy Polymers 0.000 claims abstract description 21
- 238000011282 treatment Methods 0.000 claims abstract description 17
- 229920001400 block copolymer Polymers 0.000 claims abstract description 16
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 claims abstract description 15
- 241000416162 Astragalus gummifer Species 0.000 claims abstract description 15
- AEMOLEFTQBMNLQ-YMDCURPLSA-N D-galactopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-YMDCURPLSA-N 0.000 claims abstract description 15
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 claims abstract description 15
- 239000004372 Polyvinyl alcohol Substances 0.000 claims abstract description 15
- 229920001615 Tragacanth Polymers 0.000 claims abstract description 15
- 229960000458 allantoin Drugs 0.000 claims abstract description 15
- 235000011187 glycerol Nutrition 0.000 claims abstract description 15
- FNTJVYCFNVUBOL-ZUGPOPFOSA-N kaempferol 3-O-glucuronide Chemical compound O1[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1OC1=C(C=2C=CC(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O FNTJVYCFNVUBOL-ZUGPOPFOSA-N 0.000 claims abstract description 15
- 229920001223 polyethylene glycol Polymers 0.000 claims abstract description 15
- 229920002451 polyvinyl alcohol Polymers 0.000 claims abstract description 15
- 239000000196 tragacanth Substances 0.000 claims abstract description 15
- 235000010487 tragacanth Nutrition 0.000 claims abstract description 15
- 229940116362 tragacanth Drugs 0.000 claims abstract description 15
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims abstract description 14
- 239000002202 Polyethylene glycol Substances 0.000 claims abstract description 14
- 229920001495 poly(sodium acrylate) polymer Polymers 0.000 claims abstract description 13
- 239000002994 raw material Substances 0.000 claims abstract description 13
- NNMHYFLPFNGQFZ-UHFFFAOYSA-M sodium polyacrylate Chemical compound [Na+].[O-]C(=O)C=C NNMHYFLPFNGQFZ-UHFFFAOYSA-M 0.000 claims abstract description 13
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims abstract description 12
- 229910052760 oxygen Inorganic materials 0.000 claims abstract description 12
- 239000001301 oxygen Substances 0.000 claims abstract description 12
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 claims abstract description 12
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 claims abstract description 12
- GYZLOYUZLJXAJU-UHFFFAOYSA-N diglycidyl ether Chemical compound C1OC1COCC1CO1 GYZLOYUZLJXAJU-UHFFFAOYSA-N 0.000 claims abstract description 8
- 238000003756 stirring Methods 0.000 claims description 28
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 24
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 24
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 18
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 17
- 239000008103 glucose Substances 0.000 claims description 17
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 claims description 16
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 claims description 16
- 238000000855 fermentation Methods 0.000 claims description 16
- 230000004151 fermentation Effects 0.000 claims description 16
- 239000001963 growth medium Substances 0.000 claims description 16
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 16
- 239000002609 medium Substances 0.000 claims description 16
- 241000565359 Fraxinus chinensis Species 0.000 claims description 15
- 238000011218 seed culture Methods 0.000 claims description 15
- 239000002023 wood Substances 0.000 claims description 15
- 244000276331 Citrus maxima Species 0.000 claims description 14
- 235000001759 Citrus maxima Nutrition 0.000 claims description 14
- 240000006509 Gynostemma pentaphyllum Species 0.000 claims description 14
- 235000002956 Gynostemma pentaphyllum Nutrition 0.000 claims description 14
- 244000246386 Mentha pulegium Species 0.000 claims description 14
- 235000016257 Mentha pulegium Nutrition 0.000 claims description 14
- 235000004357 Mentha x piperita Nutrition 0.000 claims description 14
- 238000010908 decantation Methods 0.000 claims description 14
- 235000001050 hortel pimenta Nutrition 0.000 claims description 14
- 239000012137 tryptone Substances 0.000 claims description 13
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 claims description 11
- 241000255789 Bombyx mori Species 0.000 claims description 8
- 244000017020 Ipomoea batatas Species 0.000 claims description 8
- 235000002678 Ipomoea batatas Nutrition 0.000 claims description 8
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 8
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 8
- 235000003704 aspartic acid Nutrition 0.000 claims description 8
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 8
- GVPFVAHMJGGAJG-UHFFFAOYSA-L cobalt dichloride Chemical compound [Cl-].[Cl-].[Co+2] GVPFVAHMJGGAJG-UHFFFAOYSA-L 0.000 claims description 8
- 239000011790 ferrous sulphate Substances 0.000 claims description 8
- 235000003891 ferrous sulphate Nutrition 0.000 claims description 8
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 claims description 8
- 229910000359 iron(II) sulfate Inorganic materials 0.000 claims description 8
- 239000004310 lactic acid Substances 0.000 claims description 8
- 235000014655 lactic acid Nutrition 0.000 claims description 8
- 229910001629 magnesium chloride Inorganic materials 0.000 claims description 8
- 229910052943 magnesium sulfate Inorganic materials 0.000 claims description 8
- 235000019341 magnesium sulphate Nutrition 0.000 claims description 8
- 235000012054 meals Nutrition 0.000 claims description 8
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 claims description 7
- 229920001592 potato starch Polymers 0.000 claims description 7
- 235000009508 confectionery Nutrition 0.000 claims description 6
- 239000000706 filtrate Substances 0.000 claims description 6
- 238000004108 freeze drying Methods 0.000 claims description 6
- 238000010438 heat treatment Methods 0.000 claims description 6
- 229940068984 polyvinyl alcohol Drugs 0.000 claims description 6
- 241000193830 Bacillus <bacterium> Species 0.000 claims description 5
- 235000009754 Vitis X bourquina Nutrition 0.000 claims description 4
- 235000012333 Vitis X labruscana Nutrition 0.000 claims description 4
- 240000006365 Vitis vinifera Species 0.000 claims description 4
- 235000014787 Vitis vinifera Nutrition 0.000 claims description 4
- 238000001914 filtration Methods 0.000 claims description 4
- 239000001888 Peptone Substances 0.000 claims description 3
- 108010080698 Peptones Proteins 0.000 claims description 3
- 235000019319 peptone Nutrition 0.000 claims description 3
- 241000589513 Burkholderia cepacia Species 0.000 claims description 2
- 235000011147 magnesium chloride Nutrition 0.000 claims description 2
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 claims description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
- 210000001643 allantois Anatomy 0.000 claims 1
- 238000004821 distillation Methods 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 abstract description 36
- 230000035876 healing Effects 0.000 abstract description 14
- 231100000241 scar Toxicity 0.000 abstract description 11
- 230000000844 anti-bacterial effect Effects 0.000 abstract description 6
- 230000000694 effects Effects 0.000 abstract description 4
- 208000025865 Ulcer Diseases 0.000 abstract description 3
- 231100000397 ulcer Toxicity 0.000 abstract description 3
- 206010052428 Wound Diseases 0.000 description 32
- 230000000052 comparative effect Effects 0.000 description 10
- 229910052739 hydrogen Inorganic materials 0.000 description 6
- 239000001257 hydrogen Substances 0.000 description 6
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 241000432824 Asparagus densiflorus Species 0.000 description 3
- 241000222122 Candida albicans Species 0.000 description 3
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 3
- 241000191967 Staphylococcus aureus Species 0.000 description 3
- 229940095731 candida albicans Drugs 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 229910052698 phosphorus Inorganic materials 0.000 description 3
- 239000011574 phosphorus Substances 0.000 description 3
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 description 2
- 244000291564 Allium cepa Species 0.000 description 2
- 235000002732 Allium cepa var. cepa Nutrition 0.000 description 2
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 2
- 125000002252 acyl group Chemical group 0.000 description 2
- 239000004964 aerogel Substances 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- IYRMWMYZSQPJKC-UHFFFAOYSA-N kaempferol Chemical compound C1=CC(O)=CC=C1C1=C(O)C(=O)C2=C(O)C=C(O)C=C2O1 IYRMWMYZSQPJKC-UHFFFAOYSA-N 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 206010004053 Bacterial toxaemia Diseases 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- UBSCDKPKWHYZNX-UHFFFAOYSA-N Demethoxycapillarisin Natural products C1=CC(O)=CC=C1OC1=CC(=O)C2=C(O)C=C(O)C=C2O1 UBSCDKPKWHYZNX-UHFFFAOYSA-N 0.000 description 1
- 241000255925 Diptera Species 0.000 description 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 206010044684 Trismus Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 238000005266 casting Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 229940042795 hydrazides for tuberculosis treatment Drugs 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- 238000005213 imbibition Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
- 235000008777 kaempferol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000012567 medical material Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- UXOUKMQIEVGVLY-UHFFFAOYSA-N morin Natural products OC1=CC(O)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UXOUKMQIEVGVLY-UHFFFAOYSA-N 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 210000004994 reproductive system Anatomy 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 208000013223 septicemia Diseases 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000012879 subculture medium Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/46—Deodorants or malodour counteractants, e.g. to inhibit the formation of ammonia or bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/28—Polysaccharides or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/40—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing ingredients of undetermined constitution or reaction products thereof, e.g. plant or animal extracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/23—Carbohydrates
- A61L2300/232—Monosaccharides, disaccharides, polysaccharides, lipopolysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/30—Compounds of undetermined constitution extracted from natural sources, e.g. Aloe Vera
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Materials Engineering (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Botany (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明提供抗感染医用创面敷料及其制备方法,其中,医用创面敷料由以下原料所制备:细菌纤维素、聚天冬酰肼、聚乙烯醇、聚丙烯酸钠、黄芪胶、尿囊素、半乳糖醛酸、醋酸甲奈氢醌、山奈酚葡萄糖醛酸苷、植物水提取物、聚氧乙烯聚氧丙烯醚嵌段共聚物、聚乙二醇二缩水甘油醚、甘油、蒸馏水。本发明制备的医用创面敷料的抗菌抗感染性好,具有广谱抗菌性;并且此敷料的愈合周期控制在一周以内,促愈效果显著,同时愈合后再生皮肤表面光滑细腻,无疤痕产生,对创面的愈合能力优秀,愈合效果良好,可适用于创伤、烧伤、溃疡等多种创面伤口治疗。
Description
技术领域
本发明属于医用材料技术领域,具体涉及抗感染医用创面敷料及其制备方法。
背景技术
皮肤是人体最大的器官,其包裹在人体整个表面,并与消化、呼吸、泌尿、生殖系统外口的粘膜上皮相连接,从而构成人体最理想的外衣,保护内脏和预防外界各种因素的侵袭。由于撕咬、挤压、摩擦、摔碰、手术等情况而出现割伤、抓伤、瘀血、砸伤、挤伤、擦伤、裂伤、刺伤、蚊虫咬伤、烧烫等创伤,这些创面必须及时处理,否则会由于病原细菌的侵入发生化脓性感染,也会造成局部出现红、肿、热、痛和功能障碍,严重时由于细菌及毒素进入血液循环可引起败血症、破伤风及毒血症等病症,严重威胁患者生命健康。
目前临床上对创伤的治疗主要采取医用敷料外敷的形式。传统敷料如天然的或合成的绷带,药棉和纱布,其主要功能是让伤口渗出液尽快蒸发,保持伤口的干燥,同时预防有害细菌对伤口的入侵。然而随着医疗技术的进步,尤其是湿性愈合理论的提出即伤口在温暖湿润的环境下能够更快速的愈合,新型敷料具有防止伤口过度干燥,抵御各种微生物预防伤口二度感染,可能抵御伤口受机械因素损害,污染和化学刺激;极大地减少电解质及能量丢失,对伤口进行全方位的保护,因此,新型医用敷料逐渐替代了传统敷料。目前新型医用敷料按其形态主要可分为纤维型、水凝胶型、薄膜型及海绵型四种,其中水凝胶敷料具有更好的吸水性、透气透湿性及生物相容性,且其原料来源广泛、价格相对便宜,因此这类敷料研究和应用更为广泛。尽管目前关于创面敷料的研究较多,但是大多水凝胶敷料在抗感染抑菌性、不留疤痕、促愈效果和吸液性等方面或多或少存在一些缺陷和不足,在一定程度上限制其应用范围。
发明内容
为此,本发明提供抗感染医用创面敷料及其制备方法,解决现有技术中上述技术问题。
为此,本发明提供抗感染医用创面敷料,由以下原料所制备,按重量份计为:细菌纤维素5-15份、聚天冬酰肼0.5-3份、聚乙烯醇0.1-1.4份、聚丙烯酸钠0.3-1份、黄芪胶2-6份、尿囊素0.6-2.5份、半乳糖醛酸0.4-1.8份、醋酸甲奈氢醌0.03-0.15份、山奈酚葡萄糖醛酸苷0.1-0.28份、植物水提取物1.2-3.2份、聚氧乙烯聚氧丙烯醚嵌段共聚物2.4-7.3份、聚乙二醇二缩水甘油醚0.5-4份、甘油15-28份、蒸馏水26-40份;
所述植物水提取物为白蜡树皮、柚皮、绞股蓝、九节木和薄荷的水提取物。
所述细菌纤维素的制备步骤为:将菌种加入种子培养基中,在20-30℃下培养10-24h,再接种至发酵培养基中,在20-30℃下培养10-24h,倾滤,即得细菌纤维素;其中,所述菌种为醋化杆菌、洋葱假单胞菌或葡萄糖杆菌;所述种子培养基包含葡萄糖、甘薯淀粉、胰蛋白胨、磷酸氢二钠、柠檬酸、硫酸镁、氯化钴;所述发酵培养基包含葡萄糖、酵母粉、胰蛋白胨、磷酸氢二钠、乳酸、乙酸、蚕蛹粉、硫酸亚铁、氯化镁、天冬氨酸。
根据本发明的一个实施方式,其中,所述细菌纤维素的制备步骤为:将菌种加入种子培养基中,在28℃下培养20h,再接种至发酵培养基中,在25℃下培养24h,倾滤,即得细菌纤维素;其中,所述菌种为醋化杆菌;所述种子培养基包含重量百分比为葡萄糖2.5%、甘薯淀粉1.3%、胰蛋白胨0.7%、磷酸氢二钠0.32%、柠檬酸0.18%、硫酸镁0.11%、氯化钴0.06%;所述发酵培养基包含重量百分比为葡萄糖2.8%、酵母粉1.2%、蚕蛹粉0.7%、胰蛋白胨0.5%、磷酸氢二钠0.27%、乳酸0.15%、乙酸0.06%、硫酸亚铁0.03%、氯化镁0.05%、天冬氨酸0.02%。
根据本发明的一个实施方式,其中,所述植物水提取物为重量份比为1:2.2:1.5:2.8:0.6的白蜡树皮、柚皮、绞股蓝、九节木和薄荷的水提取物。
根据本发明的一个实施方式,其中,所述植物水提取物的制备步骤为:将白蜡树皮、柚皮、绞股蓝、九节木和薄荷先经500W微波处理5-15min,然后干燥并粉碎,置于10-30倍蒸馏水中,于500W功率下微波处理20-60min,冷却至室温,倾滤,再置于10-30倍蒸馏水中重复进行上述微波处理步骤3-5次,过滤,合并滤液,并蒸发水份至膏状,即得。
根据本发明的一个实施方式,所述的抗感染医用创面敷料,由以下原料所制备,按重量份计为:细菌纤维素5.7-13.2份、聚天冬酰肼0.8-2.4份、聚乙烯醇0.4-1.2份、聚丙烯酸钠0.4-0.8份、黄芪胶2.5-5.6份、尿囊素0.8-2.2份、半乳糖醛酸0.7-1.4份、醋酸甲奈氢醌0.05-0.13份、山奈酚葡萄糖醛酸苷0.14-0.22份、植物水提取物1.3-3份、聚氧乙烯聚氧丙烯醚嵌段共聚物2.8-6.2份、聚乙二醇二缩水甘油醚0.6-3.5份、甘油18-27份、蒸馏水30-38份。
为此,本发明提供抗感染医用创面敷料的制备方法,包括如下制备步骤:
1)将细菌纤维素置于加入10-20倍重量份的70-85℃,0.5-1.2wt.%的NaOH溶液中,以50-200r/min转速搅拌50-150min,过滤并漂洗至中性,冷冻干燥,即得预处理细菌纤维素;
2)将聚乙烯醇、黄芪胶、尿囊素、半乳糖醛酸加入蒸馏水中,加热至60-80℃搅拌30-80min,得溶液M;
3)将聚丙烯酸钠、醋酸甲奈氢醌、聚天冬酰肼和山奈酚葡萄糖醛酸苷加入甘油中,加热至40-55℃搅拌20-50min,得溶液N;
4)将溶液M加入反应釜中,边搅拌边加入步骤1)制得的预处理细菌纤维素,搅拌15-30min,然后加入植物水提取物和聚氧乙烯聚氧丙烯醚嵌段共聚物,搅拌30-50min;
5)随后将步骤3)制得的溶液N加入反应釜中,搅拌混合均匀后,加入聚乙二醇二缩水甘油醚,混合均匀,倒入模具中,在50-65℃下搅拌混合2-4h,冷却至室温,即得。
本发明的有益效果为:
本发明制备的医用创面敷料的抗菌抗感染性好,对铜绿假单胞菌、金黄色葡萄球菌和白色念珠菌的抑制率分别达到96.5%、97.3%和97.8%及其以上,具有广谱抗菌性;并且此敷料的愈合周期控制在一周以内,促愈效果显著,同时愈合后再生皮肤表面光滑细腻,无疤痕产生,对创面的愈合能力优秀,愈合效果良好,可适用于创伤、烧伤、溃疡等多种创面伤口治疗。
具体实施方式
下面结合实施例,对本发明作进一步详细描述。以下实施例用于说明本发明,但不用来限制本发明的范围。
实施例1
抗感染医用创面敷料,由以下原料所制备,按重量份计为:细菌纤维素5份、聚天冬酰肼0.5份、聚乙烯醇0.1份、聚丙烯酸钠0.3份、黄芪胶2份、尿囊素0.6份、半乳糖醛酸0.4份、醋酸甲奈氢醌0.03份、山奈酚葡萄糖醛酸苷0.1份、植物水提取物1.2份、聚氧乙烯聚氧丙烯醚嵌段共聚物2.4份、聚乙二醇二缩水甘油醚0.5份、甘油15份、蒸馏水26份。
所述细菌纤维素的制备步骤为:将菌种加入种子培养基中,在20℃下培养10h,再接种至发酵培养基中,在20℃下培养10h,倾滤,即得细菌纤维素;其中,所述菌种为葡萄糖杆菌;所述种子培养基包含重量百分比为葡萄糖2.5%、甘薯淀粉1.3%、胰蛋白胨0.7%、磷酸氢二钠0.32%、柠檬酸0.18%、硫酸镁0.11%、氯化钴0.06%;所述发酵培养基包含重量百分比为葡萄糖2.8%、酵母粉1.2%、蚕蛹粉0.7%、胰蛋白胨0.5%、磷酸氢二钠0.27%、乳酸0.15%、乙酸0.06%、硫酸亚铁0.03%、氯化镁0.05%、天冬氨酸0.02%。
所述植物水提取物重量份比为1:2.6:1.8:2.1:0.4的白蜡树皮、柚皮、绞股蓝、九节木和薄荷的水提取物;所述植物水提取物的制备步骤为:将白蜡树皮、柚皮、绞股蓝、九节木和薄荷先经500W微波处理5min,然后干燥并粉碎,置于10倍蒸馏水中,于500W功率下微波处理20min,冷却至室温,倾滤,再置于10倍蒸馏水中重复进行上述微波处理步骤3次,过滤,合并滤液,并蒸发水份至膏状,即得。
上述抗感染医用创面敷料的制备方法,包括如下制备步骤:
1)将细菌纤维素置于加入10倍重量份的70℃,0.5wt.%的NaOH溶液中,以50r/min转速搅拌50min,过滤并漂洗至中性,冷冻干燥,即得预处理细菌纤维素;
2)将聚乙烯醇、黄芪胶、尿囊素、半乳糖醛酸加入蒸馏水中,加热至60℃搅拌30min,得溶液M;
3)将聚丙烯酸钠、醋酸甲奈氢醌、聚天冬酰肼和山奈酚葡萄糖醛酸苷加入甘油中,加热至40℃搅拌20min,得溶液N;
4)将溶液M加入反应釜中,边搅拌边加入步骤1)制得的预处理细菌纤维素,搅拌15min,然后加入植物水提取物和聚氧乙烯聚氧丙烯醚嵌段共聚物,搅拌30min;
5)随后将步骤3)制得的溶液N加入反应釜中,搅拌混合均匀后,加入聚乙二醇二缩水甘油醚,混合均匀,倒入模具中,在50℃下搅拌混合2h,冷却至室温,即得。
实施例2
抗感染医用创面敷料,由以下原料所制备,按重量份计为:细菌纤维素15份、聚天冬酰肼3份、聚乙烯醇1.4份、聚丙烯酸钠1份、黄芪胶6份、尿囊素2.5份、半乳糖醛酸1.8份、醋酸甲奈氢醌0.15份、山奈酚葡萄糖醛酸苷0.28份、植物水提取物3.2份、聚氧乙烯聚氧丙烯醚嵌段共聚物7.3份、聚乙二醇二缩水甘油醚4份、甘油28份、蒸馏水40份。
所述细菌纤维素的制备步骤为:将菌种加入种子培养基中,在30℃下培养24h,再接种至发酵培养基中,在30℃下培养24h,倾滤,即得细菌纤维素;其中,所述菌种为洋葱假单胞菌;所述种子培养基包含重量百分比为葡萄糖2.5%、甘薯淀粉1.3%、胰蛋白胨0.7%、磷酸氢二钠0.32%、柠檬酸0.18%、硫酸镁0.11%、氯化钴0.06%;所述发酵培养基包含重量百分比为葡萄糖2.8%、酵母粉1.2%、蚕蛹粉0.7%、胰蛋白胨0.5%、磷酸氢二钠0.27%、乳酸0.15%、乙酸0.06%、硫酸亚铁0.03%、氯化镁0.05%、天冬氨酸0.02%。
所述植物水提取物重量份比为1:1.5:1:2.4:1.6的白蜡树皮、柚皮、绞股蓝、九节木和薄荷的水提取物;所述植物水提取物的制备步骤为:将白蜡树皮、柚皮、绞股蓝、九节木和薄荷先经500W微波处理15min,然后干燥并粉碎,置于30倍蒸馏水中,于500W功率下微波处理60min,冷却至室温,倾滤,再置于30倍蒸馏水中重复进行上述微波处理步骤5次,过滤,合并滤液,并蒸发水份至膏状,即得。
上述抗感染医用创面敷料的制备方法,包括如下制备步骤:
1)将细菌纤维素置于加入20倍重量份的85℃,1.2wt.%的NaOH溶液中,以200r/min转速搅拌150min,过滤并漂洗至中性,冷冻干燥,即得预处理细菌纤维素;
2)将聚乙烯醇、黄芪胶、尿囊素、半乳糖醛酸加入蒸馏水中,加热至80℃搅拌80min,得溶液M;
3)将聚丙烯酸钠、醋酸甲奈氢醌、聚天冬酰肼和山奈酚葡萄糖醛酸苷加入甘油中,加热至55℃搅拌50min,得溶液N;
4)将溶液M加入反应釜中,边搅拌边加入步骤1)制得的预处理细菌纤维素,搅拌30min,然后加入植物水提取物和聚氧乙烯聚氧丙烯醚嵌段共聚物,搅拌50min;
5)随后将步骤3)制得的溶液N加入反应釜中,搅拌混合均匀后,加入聚乙二醇二缩水甘油醚,混合均匀,倒入模具中,在65℃下搅拌混合4h,冷却至室温,即得。
实施例3
抗感染医用创面敷料,由以下原料所制备,按重量份计为:细菌纤维素5.7份、聚天冬酰肼0.8份、聚乙烯醇0.4份、聚丙烯酸钠0.4份、黄芪胶2.5份、尿囊素0.8份、半乳糖醛酸0.7份、醋酸甲奈氢醌0.05份、山奈酚葡萄糖醛酸苷0.14份、植物水提取物1.3份、聚氧乙烯聚氧丙烯醚嵌段共聚物2.8份、聚乙二醇二缩水甘油醚0.6份、甘油18份、蒸馏水30份。
所述细菌纤维素的制备步骤为:将菌种加入种子培养基中,在25℃下培养18h,再接种至发酵培养基中,在25℃下培养24h,倾滤,即得细菌纤维素;其中,所述菌种为醋化杆菌;所述种子培养基包含重量百分比为葡萄糖2.5%、甘薯淀粉1.3%、胰蛋白胨0.7%、磷酸氢二钠0.32%、柠檬酸0.18%、硫酸镁0.11%、氯化钴0.06%;所述发酵培养基包含重量百分比为葡萄糖2.8%、酵母粉1.2%、蚕蛹粉0.7%、胰蛋白胨0.5%、磷酸氢二钠0.27%、乳酸0.15%、乙酸0.06%、硫酸亚铁0.03%、氯化镁0.05%、天冬氨酸0.02%。
所述植物水提取物重量份比为1:2.2:1.5:2.8:0.6的白蜡树皮、柚皮、绞股蓝、九节木和薄荷的水提取物;所述植物水提取物的制备步骤为:将白蜡树皮、柚皮、绞股蓝、九节木和薄荷先经500W微波处理10min,然后干燥并粉碎,置于20倍蒸馏水中,于500W功率下微波处理40min,冷却至室温,倾滤,再置于25倍蒸馏水中重复进行上述微波处理步骤5次,过滤,合并滤液,并蒸发水份至膏状,即得。
上述抗感染医用创面敷料的制备方法,包括如下制备步骤:
1)将细菌纤维素置于加入18倍重量份的78℃,0.8wt.%的NaOH溶液中,以150r/min转速搅拌70min,过滤并漂洗至中性,冷冻干燥,即得预处理细菌纤维素;
2)将聚乙烯醇、黄芪胶、尿囊素、半乳糖醛酸加入蒸馏水中,加热至70℃搅拌65min,得溶液M;
3)将聚丙烯酸钠、醋酸甲奈氢醌、聚天冬酰肼和山奈酚葡萄糖醛酸苷加入甘油中,加热至48℃搅拌40min,得溶液N;
4)将溶液M加入反应釜中,边搅拌边加入步骤1)制得的预处理细菌纤维素,搅拌25min,然后加入植物水提取物和聚氧乙烯聚氧丙烯醚嵌段共聚物,搅拌40min;
5)随后将步骤3)制得的溶液N加入反应釜中,搅拌混合均匀后,加入聚乙二醇二缩水甘油醚,混合均匀,倒入模具中,在58℃下搅拌混合4h,冷却至室温,即得。
实施例4
抗感染医用创面敷料,由以下原料所制备,按重量份计为:细菌纤维素13.2份、聚天冬酰肼2.4份、聚乙烯醇1.2份、聚丙烯酸钠0.8份、黄芪胶5.6份、尿囊素2.2份、半乳糖醛酸1.4份、醋酸甲奈氢醌0.13份、山奈酚葡萄糖醛酸苷0.22份、植物水提取物3份、聚氧乙烯聚氧丙烯醚嵌段共聚物6.2份、聚乙二醇二缩水甘油醚3.5份、甘油27份、蒸馏水38份。
所述细菌纤维素的制备步骤为:将菌种加入种子培养基中,在28℃下培养18h,再接种至发酵培养基中,在25℃下培养16h,倾滤,即得细菌纤维素;其中,所述菌种为洋葱假单胞菌;所述种子培养基包含重量百分比为葡萄糖2.5%、甘薯淀粉1.3%、胰蛋白胨0.7%、磷酸氢二钠0.32%、柠檬酸0.18%、硫酸镁0.11%、氯化钴0.06%;所述发酵培养基包含重量百分比为葡萄糖2.8%、酵母粉1.2%、蚕蛹粉0.7%、胰蛋白胨0.5%、磷酸氢二钠0.27%、乳酸0.15%、乙酸0.06%、硫酸亚铁0.03%、氯化镁0.05%、天冬氨酸0.02%。
所述植物水提取物重量份比为1:2.2:1.5:2.8:0.6的白蜡树皮、柚皮、绞股蓝、九节木和薄荷的水提取物;所述植物水提取物的制备步骤为:将白蜡树皮、柚皮、绞股蓝、九节木和薄荷先经500W微波处理10min,然后干燥并粉碎,置于25倍蒸馏水中,于500W功率下微波处理40min,冷却至室温,倾滤,再置于20倍蒸馏水中重复进行上述微波处理步骤4次,过滤,合并滤液,并蒸发水份至膏状,即得。
上述抗感染医用创面敷料的制备方法,包括如下制备步骤:
1)将细菌纤维素置于加入18倍重量份的75℃,0.8wt.%的NaOH溶液中,以180r/min转速搅拌75min,过滤并漂洗至中性,冷冻干燥,即得预处理细菌纤维素;
2)将聚乙烯醇、黄芪胶、尿囊素、半乳糖醛酸加入蒸馏水中,加热至75℃搅拌55min,得溶液M;
3)将聚丙烯酸钠、醋酸甲奈氢醌、聚天冬酰肼和山奈酚葡萄糖醛酸苷加入甘油中,加热至40-55℃搅拌45min,得溶液N;
4)将溶液M加入反应釜中,边搅拌边加入步骤1)制得的预处理细菌纤维素,搅拌25min,然后加入植物水提取物和聚氧乙烯聚氧丙烯醚嵌段共聚物,搅拌50min;
5)随后将步骤3)制得的溶液N加入反应釜中,搅拌混合均匀后,加入聚乙二醇二缩水甘油醚,混合均匀,倒入模具中,在58℃下搅拌混合4h,冷却至室温,即得。
对比例1
本对比例中与实施例1的不同之处为:不添加聚氧乙烯聚氧丙烯醚嵌段共聚物、尿囊素和醋酸甲奈氢醌,其他原料及其含量和制备方法同实施例1。
对比例2
本对比例中与实施例1的不同之处为:不添加聚天冬酰肼、山奈酚葡萄糖醛酸苷及其相关步骤,其他原料及其含量和制备方法同实施例1。
对比例3
本对比例中与实施例1的不同之处为:所述植物水提取物中不添加九节木和白蜡树皮,同时所述细菌纤维素采用葡萄糖杆菌通过常规的培养基和培养方法所制备而得,其他原料及其含量和制备方法同实施例1。
下面为以上各实施例和对比例所制备的医用创面敷料产品的按照行业标准进行相关性能检测,其具体检测结果为:
| 抑菌率/%(铜绿假单胞菌) | 抑菌率/%(金黄色葡萄球菌) | 抑菌率/%(白色念珠菌) | 愈合周期/天 | 愈合效果 | |
| 实施例1 | 96.5 | 97.3 | 97.8 | 5-7 | 无疤痕 |
| 实施例2 | 98.2 | 98.7 | 99.0 | 5-6 | 无疤痕 |
| 实施例3 | 99.1 | 99.4 | 99.2 | 4-5 | 无疤痕 |
| 实施例4 | 99.5 | 99.7 | 99.7 | 3-4 | 无疤痕 |
| 对比例1 | 87.5 | 88.3 | 86.4 | 8-9 | 无疤痕 |
| 对比例2 | 78.2 | 84.7 | 82.5 | 8-10 | 轻微疤痕 |
| 对比例3 | 71.6 | 74.5 | 67.6 | 9-12 | 中度疤痕 |
由以上测试结果可知,本发明制备的医用创面敷料的抗菌抗感染性好,对铜绿假单胞菌、金黄色葡萄球菌和白色念珠菌的抑制率分别达到96.5%、97.3%和97.8%及其以上,具有广谱抗菌性;并且此敷料的愈合周期控制在一周以内,促愈效果显著,同时愈合后再生皮肤表面光滑细腻,无疤痕产生,对创面的愈合能力优秀,愈合效果良好,可适用于创伤、烧伤、溃疡等多种创面伤口治疗。
Claims (6)
1.抗感染医用创面敷料,其特征在于,由以下原料所制备,按重量份计为:细菌纤维素5-15份、聚天冬酰肼0.5-3份、聚乙烯醇0.1-1.4份、聚丙烯酸钠0.3-1份、黄芪胶2-6份、尿囊素0.6-2.5份、半乳糖醛酸0.4-1.8份、醋酸甲奈氢醌0.03-0.15份、山奈酚葡萄糖醛酸苷0.1-0.28份、植物水提取物1.2-3.2份、聚氧乙烯聚氧丙烯醚嵌段共聚物2.4-7.3份、聚乙二醇二缩水甘油醚0.5-4份、甘油15-28份、蒸馏水26-40份;
所述植物水提取物为白蜡树皮、柚皮、绞股蓝、九节木和薄荷的水提取物;
所述细菌纤维素的制备步骤为:将菌种加入种子培养基中,在20-30℃下培养10-24h,再接种至发酵培养基中,在20-30℃下培养10-24h,倾滤,即得细菌纤维素;其中,所述菌种为醋化杆菌、洋葱假单胞菌或葡萄糖杆菌;所述种子培养基包含葡萄糖、甘薯淀粉、胰蛋白胨、磷酸氢二钠、柠檬酸、硫酸镁、氯化钴;所述发酵培养基包含葡萄糖、酵母粉、胰蛋白胨、磷酸氢二钠、乳酸、乙酸、蚕蛹粉、硫酸亚铁、氯化镁、天冬氨酸。
2.根据权利要求1所述的抗感染医用创面敷料,其特征在于,所述细菌纤维素的制备步骤为:将菌种加入种子培养基中,在28℃下培养20h,再接种至发酵培养基中,在25℃下培养24h,倾滤,即得细菌纤维素;其中,所述菌种为醋化杆菌;所述种子培养基包含重量百分比为葡萄糖2.5%、甘薯淀粉1.3%、胰蛋白胨0.7%、磷酸氢二钠0.32%、柠檬酸0.18%、硫酸镁0.11%、氯化钴0.06%;所述发酵培养基包含重量百分比为葡萄糖2.8%、酵母粉1.2%、蚕蛹粉0.7%、胰蛋白胨0.5%、磷酸氢二钠0.27%、乳酸0.15%、乙酸0.06%、硫酸亚铁0.03%、氯化镁0.05%、天冬氨酸0.02%。
3.根据权利要求1所述的抗感染医用创面敷料,其特征在于,所述植物水提取物为重量份比为1:2.2:1.5:2.8:0.6的白蜡树皮、柚皮、绞股蓝、九节木和薄荷的水提取物。
4.根据权利要求1所述的抗感染医用创面敷料,其特征在于,所述植物水提取物的制备步骤为:将白蜡树皮、柚皮、绞股蓝、九节木和薄荷先经500W微波处理5-15min,然后干燥并粉碎,置于10-30倍蒸馏水中,于500W功率下微波处理20-60min,冷却至室温,倾滤,再置于10-30倍蒸馏水中重复进行上述微波处理步骤3-5次,过滤,合并滤液,并蒸发水份至膏状,即得。
5.根据权利要求1-4任一所述的抗感染医用创面敷料,其特征在于,由以下原料所制备,按重量份计为:细菌纤维素5.7-13.2份、聚天冬酰肼0.8-2.4份、聚乙烯醇0.4-1.2份、聚丙烯酸钠0.4-0.8份、黄芪胶2.5-5.6份、尿囊素0.8-2.2份、半乳糖醛酸0.7-1.4份、醋酸甲奈氢醌0.05-0.13份、山奈酚葡萄糖醛酸苷0.14-0.22份、植物水提取物1.3-3份、聚氧乙烯聚氧丙烯醚嵌段共聚物2.8-6.2份、聚乙二醇二缩水甘油醚0.6-3.5份、甘油18-27份、蒸馏水30-38份。
6.如权利要求1-5任一所述的抗感染医用创面敷料的制备方法,其特征在于,包括如下制备步骤:
1)将细菌纤维素置于加入10-20倍重量份的70-85℃,0.5-1.2wt.%的NaOH溶液中,以50-200r/min转速搅拌50-150min,过滤并漂洗至中性,冷冻干燥,即得预处理细菌纤维素;
2)将聚乙烯醇、黄芪胶、尿囊素、半乳糖醛酸加入蒸馏水中,加热至60-80℃搅拌30-80min,得溶液M;
3)将聚丙烯酸钠、醋酸甲奈氢醌、聚天冬酰肼和山奈酚葡萄糖醛酸苷加入甘油中,加热至40-55℃搅拌20-50min,得溶液N;
4)将溶液M加入反应釜中,边搅拌边加入步骤1)制得的预处理细菌纤维素,搅拌15-30min,然后加入植物水提取物和聚氧乙烯聚氧丙烯醚嵌段共聚物,搅拌30-50min;
5)随后将步骤3)制得的溶液N加入反应釜中,搅拌混合均匀后,加入聚乙二醇二缩水甘油醚,混合均匀,倒入模具中,在50-65℃下搅拌混合2-4h,冷却至室温,即得。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710515624.0A CN107397975A (zh) | 2017-06-29 | 2017-06-29 | 抗感染医用创面敷料及其制备方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710515624.0A CN107397975A (zh) | 2017-06-29 | 2017-06-29 | 抗感染医用创面敷料及其制备方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107397975A true CN107397975A (zh) | 2017-11-28 |
Family
ID=60405098
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710515624.0A Pending CN107397975A (zh) | 2017-06-29 | 2017-06-29 | 抗感染医用创面敷料及其制备方法 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107397975A (zh) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108578749A (zh) * | 2018-07-11 | 2018-09-28 | 淮阴工学院 | 一种可载药缓释的医用复合柚皮果胶海绵敷料及其制备方法和应用 |
| CN108867048A (zh) * | 2018-06-06 | 2018-11-23 | 吴江康欣医用敷料有限公司 | 一种可快速止血手术纱布的制备方法及其应用 |
| CN112274548A (zh) * | 2020-10-24 | 2021-01-29 | 北京中康联健康科技有限公司 | 一种具有愈伤功效的组合物及其制备方法和应用 |
| CN112294539A (zh) * | 2020-11-19 | 2021-02-02 | 嘉兴学院 | 一种干爽抑菌型防溢乳垫 |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101745141A (zh) * | 2010-01-15 | 2010-06-23 | 东华大学 | 用于急性创伤的细菌纤维素基抗菌干膜及其制备方法和应用 |
| CN105727360A (zh) * | 2016-03-23 | 2016-07-06 | 成都超吉科技有限公司 | 用于手术皮肤切口、感染性和非感染性创面的生物材料及其应用 |
| CN106075592A (zh) * | 2015-05-29 | 2016-11-09 | 杭州弘复医疗科技有限公司 | 作为再生性皮肤替代物的多功能皮肤或创面复合敷料 |
| CN106267310A (zh) * | 2016-08-16 | 2017-01-04 | 仇颖莹 | 一种复合细菌纤维素医用敷料的制备方法 |
| CN106668932A (zh) * | 2016-10-24 | 2017-05-17 | 北京化工大学 | 一种止血材料及其制备方法与应用 |
-
2017
- 2017-06-29 CN CN201710515624.0A patent/CN107397975A/zh active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101745141A (zh) * | 2010-01-15 | 2010-06-23 | 东华大学 | 用于急性创伤的细菌纤维素基抗菌干膜及其制备方法和应用 |
| CN106075592A (zh) * | 2015-05-29 | 2016-11-09 | 杭州弘复医疗科技有限公司 | 作为再生性皮肤替代物的多功能皮肤或创面复合敷料 |
| CN105727360A (zh) * | 2016-03-23 | 2016-07-06 | 成都超吉科技有限公司 | 用于手术皮肤切口、感染性和非感染性创面的生物材料及其应用 |
| CN106267310A (zh) * | 2016-08-16 | 2017-01-04 | 仇颖莹 | 一种复合细菌纤维素医用敷料的制备方法 |
| CN106668932A (zh) * | 2016-10-24 | 2017-05-17 | 北京化工大学 | 一种止血材料及其制备方法与应用 |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108867048A (zh) * | 2018-06-06 | 2018-11-23 | 吴江康欣医用敷料有限公司 | 一种可快速止血手术纱布的制备方法及其应用 |
| CN108578749A (zh) * | 2018-07-11 | 2018-09-28 | 淮阴工学院 | 一种可载药缓释的医用复合柚皮果胶海绵敷料及其制备方法和应用 |
| CN112274548A (zh) * | 2020-10-24 | 2021-01-29 | 北京中康联健康科技有限公司 | 一种具有愈伤功效的组合物及其制备方法和应用 |
| CN112294539A (zh) * | 2020-11-19 | 2021-02-02 | 嘉兴学院 | 一种干爽抑菌型防溢乳垫 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI398275B (zh) | 皮膚創傷敷料及其製備方法 | |
| CN107397975A (zh) | 抗感染医用创面敷料及其制备方法 | |
| CN103536954B (zh) | 一种交联海藻酸-细菌纤维素海绵及其制备方法 | |
| CN102212208A (zh) | 细菌纤维素/透明质酸复合材料的制备方法 | |
| CN105106292A (zh) | 多糖生物医用胶体液及制备方法 | |
| CN103357060B (zh) | 一种细菌纤维素复合鱼胶原蛋白伤口敷料的制备方法 | |
| CN104587519B (zh) | 一种含有中药的敷料贴 | |
| CN105126159A (zh) | 一种多糖生物医用胶体液及其制备方法 | |
| CN105903059A (zh) | 一种抑菌医用功能敷料 | |
| CN104887715B (zh) | 一种枯草芽孢杆菌喷雾剂 | |
| CN103394113B (zh) | 一种创可贴 | |
| CN103893816B (zh) | 含植物成分的细菌纤维素复合羊膜细胞外基质敷料制备方法 | |
| CN111848985B (zh) | 石斛提取物-纳米纤维素复合水凝胶的制备方法及产品及用途 | |
| CN110403858A (zh) | 细菌纤维素/普洱茶提取物复合功能材料及其制备方法 | |
| CN112426562A (zh) | 一种促进伤口愈合的纯天然医用敷料 | |
| CN103736146B (zh) | 一种载银无纺布的制备方法 | |
| CN107510861A (zh) | 一种创面修复壳聚糖凝胶 | |
| CN113559311B (zh) | 一种医用抗菌止血凝胶敷料及其制备方法 | |
| CN105126149A (zh) | 一种医用复合壳聚糖敷贴 | |
| CN105688271A (zh) | 一种创伤修复蜂胶敷料及其制备方法 | |
| CN105854064A (zh) | 一种透气止血型藻酸盐敷料及其制备方法 | |
| CN105920656A (zh) | 一种三七茎叶资源化制备医用止血海绵的方法 | |
| CN107320764A (zh) | 一种保湿透气医用敷料及其制备方法 | |
| CN108785363A (zh) | 黄檀属植物香材在制备治疗微生物感染的药物中的应用 | |
| CN110965320A (zh) | 一种负氧离子地毯的制备工艺 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20171128 |